First Trust Advisors LP Raises Holdings in Solventum Corporation $SOLV

First Trust Advisors LP increased its stake in shares of Solventum Corporation (NYSE:SOLV) by 57.4% during the 1st quarter, Holdings Channel reports. The fund owned 334,441 shares of the company’s stock after purchasing an additional 121,989 shares during the quarter. First Trust Advisors LP’s holdings in Solventum were worth $21,839,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SOLV. CrossGen Wealth LLC purchased a new position in Solventum during the fourth quarter valued at approximately $25,000. Measured Wealth Private Client Group LLC purchased a new stake in Solventum in the 3rd quarter worth approximately $25,000. Clearstead Trust LLC grew its stake in shares of Solventum by 61.0% during the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock worth $26,000 after purchasing an additional 150 shares during the period. JNBA Financial Advisors increased its holdings in shares of Solventum by 205.4% during the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after purchasing an additional 228 shares in the last quarter. Finally, CYBER HORNET ETFs LLC purchased a new position in shares of Solventum during the 2nd quarter valued at approximately $28,000.

Solventum Trading Up 2.8%

Shares of NYSE:SOLV opened at $88.56 on Thursday. Solventum Corporation has a 1 year low of $62.38 and a 1 year high of $88.65. The firm has a market capitalization of $15.34 billion, a price-to-earnings ratio of 10.85, a price-to-earnings-growth ratio of 1.33 and a beta of 0.66. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The business’s 50 day moving average price is $78.03 and its 200-day moving average price is $74.19.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.35 by $0.13. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm’s revenue was down 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, equities research analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. BMO Capital Markets initiated coverage on shares of Solventum in a report on Wednesday, July 8th. They set a “market perform” rating and a $81.00 price target on the stock. Piper Sandler cut their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a report on Friday, April 17th. KeyCorp upped their price objective on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. UBS Group raised shares of Solventum from a “neutral” rating to a “buy” rating and set a $95.00 target price on the stock in a research note on Tuesday. Finally, Weiss Ratings upgraded Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, July 17th. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $86.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.